Skip to main content

Cardiometabolic HFpEF with focus on type 2 diabetes mellitus

Edited by:
Professor Francesco Paneni, MD, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland                         
Dr. Era Gorica, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland

Submission Status: Open   |   Submission Deadline: 20 November 2024


Cardiovascular Diabetology is calling for submissions to our Collection on Cardiometabolic HFpEF with focus on type 2 diabetes mellitus. This collection aims to highlight the complex interplay between metabolic factors and heart failure with preserved ejection fraction (HFpEF), particularly focusing on type 2 diabetes (T2D). Described as the “single largest unmet need in cardiovascular medicine”, HFpEF has come to represent more than half of all new heart failure diagnoses and associates with a poor 5-year prognosis (40% mortality rate) despite optimal medical treatment. Obesity and diabetes-related HFpEF, also known as cardiometabolic HFpEF (HFpEF), is the most prevalent HFpEF phenotype and its incidence is expected to increase exponentially in decades to come. The presence of T2D contributes to disease development and progression through mechanisms such as insulin resistance, chronic inflammation, endothelial dysfunction, immune dysregulation and myocardial fibrosis. This collection welcomes original articles, meta-analyses and review articles that explore a range of topics from mechanistic studies and therapeutic targets to clinical aspects, pharmacology, epidemiology, and advanced imaging techniques. Our goal is to provide a comprehensive and state-of-the-art overview of this critical area, highlighting the multifaceted nature of HFpEF in cardiometabolic health. This collection aims to bridge the gap between research and clinical application, offering invaluable knowledge for both healthcare professionals and researchers dedicated to improving cardiovascular health. Specifically, the issue will cover the following topics:

• Molecular mechanisms of diabetic HFpEF

• HFpEF and cardiometabolic disease

• Prevalence, risk prediction and prognosis of diabetic HFpEF

• Diabetes and hypertension in HFpEF

• GLP1-RA and SGLT2i in HFpEF

• Artificial intelligence-based approaches in diabetic HFpEF

• Sex and gender in diabetic HFpEF

• Comorbidities in diabetic HFpEF

Image credit: Francesco Paneni and Era Gorica

New Content ItemThis collection supports and amplifies research related to SDG 3: Good health and well-being. 

Meet the Guest Editors

Back to top

Professor Francesco Paneni, MD, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland 

Francesco Paneni is Professor of Cardiology at the University of Zürich and Head of the Cardiometabolic Division at the Department of Cardiology, Zürich University Hospital. He is also Director of the Center for Translational and Experimental Cardiology (CTEC) and Co-Director of Translational Research within the Department of Cardiology. He earned his MD and PhD at the University of Rome “Sapienza”. During his training in Cardiology, he worked as research fellow at Mount Sinai Medical Center in New York under the supervision of Prof. Valentin Fuster. After his PhD, he trained as a post-doctoral fellow at the Institute of Cardiovascular Physiology, University of Zürich, and the Center for Molecular Medicine (CMM) at Karolinska Institute, Sweden. The goal of Paneni’s research is to characterize the epigenetic mechanisms (DNA methylation, histone modifications and non-coding RNAs) of myocardial and vascular damage in the setting of obesity and diabetes. A main interest of his lab is to understand the mechanisms and the pathophysiology of cardiometabolic HFpEF.

Dr. Era Gorica, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland

Era Gorica is a postdoctoral researcher at Center for Translational and Experimental Cardiology (CTEC) at the University of Zürich and University Hospital Zürich. She holds a degree in Pharmacy from Albanian University, Albania, and furthered her studies with a doctorate from the University of Pisa, Italy. During her doctoral program, she received specialized training through an exchange program at the University of Zurich and currently works within Prof. Paneni unit at CTEC.

  1. Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea...

    Authors: Arif Albulushi, Desmond Boakye Tanoh, Ahmed Almustafa, Nadya Al Matrooshi, Ronald Zolty and Brian Lowes
    Citation: Cardiovascular Diabetology 2024 23:324
    Content type: Research Published on:

  2. Patients with diabetes have an increased risk of developing heart failure with preserved ejection fraction (HFpEF). This study aimed to compare indices of myocardial deformation and perfusion between patients ...

    Authors: Xin-Ni Li, Yu-Ting Liu, Sang Kang, Dan Zeng Qu Yang, Huo-Yuan Xiao, Wen-Kun Ma, Cheng-Xing Shen and Jing-Wei Pan
    Citation: Cardiovascular Diabetology 2024 23:303
    Content type: Research Published on:

  3. Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred...

    Authors: Salmina J. Guivala, Konrad A. Bode, Jürgen G. Okun, Ece Kartal, Edzard Schwedhelm, Luca V. Pohl, Sarah Werner, Sandra Erbs, Holger Thiele and Petra Büttner
    Citation: Cardiovascular Diabetology 2024 23:299
    Content type: Research Published on:

  4. We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati...

    Authors: Matteo Landolfo, Francesco Spannella, Federico Giulietti, Beatrice Ortensi, Lucia Stella, Maria A. Carlucci, Roberta Galeazzi, Federica Turchi, Maria P. Luconi, Roberto Zampa, Sofia Cecchi, Elena Tortato, Massimiliano Petrelli and Riccardo Sarzani
    Citation: Cardiovascular Diabetology 2024 23:297
    Content type: Research Published on:

  5. Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mec...

    Authors: Ying Shi, Lili Zhao, Jing Wang, Xiankun Liu, Yiming Bai, Hongliang Cong and Ximing Li
    Citation: Cardiovascular Diabetology 2024 23:269
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original articles, meta-analyses and review articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Cardiometabolic HFpEF with focus on type 2 diabetes mellitus" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.